Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...

Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...

Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...

Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...

Roche's sale of InterMune and Esbriet in the US comes as Boehringer revealed its own follow-up play in the IPF, category, ...

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.